ImmunityBio Price Target Lifted to $15 After EU Approval Expands Anktiva to 33 Countries
H.C. Wainwright raised ImmunityBio’s price target 50% to $15 and maintained a Buy rating after EU approval broadened Anktiva’s market to 33 countries. The company reported Q4 EPS loss of $0.06 versus $0.10 expected and revenue of $38.29M compared to $37.78M consensus.
1. Analyst Price Target Upgrade
H.C. Wainwright increased its price target on ImmunityBio from $10 to $15 and reiterated a Buy rating, citing European Union approval of Anktiva in 33 countries. The firm noted that regulatory clearance removes a major overhang and unlocks substantial incremental commercial opportunities.
2. Q4 Financial Results
In Q4, ImmunityBio reported a net loss per share of $0.06, narrower than the $0.10 consensus estimate, and generated revenue of $38.29 million, slightly above the $37.78 million consensus. These results reflect growing market traction for its bladder cancer immunotherapy.
3. Commercial Expansion and Partnerships
The company has deployed over 100 commercial professionals through its Accord Healthcare partnership in 30 European countries and is collaborating with BioPharma & Cigalah to drive sales in Saudi Arabia and the broader MENA region. Subsidiaries in Dublin and the Kingdom of Saudi Arabia provide infrastructure to support operations across all 33 authorized markets.
4. Clinical and Future Milestones
ImmunityBio is focused on completing enrollment in its BCG-naive randomized trial with a Biologics License Application filing targeted by Q4 2026. It is also pursuing label expansions into lung cancer and lymphopenia while aiming to translate its 700% revenue growth trajectory into lasting shareholder value.